Preparation process for (R)-3-benzene dicarboximide piperidine tartrate

A technology of phthalimide piperidine and tartrate, which is applied in the field of preparation technology of (R)-3-phthalimide piperidine tartrate, and can solve the problem of wasting 3-phthalimide Piperidine, unfavorable large-scale production, total yield and other problems, to achieve the effects of simple post-processing and purification operations, low equipment requirements, and simple operation

CN102372691AInactive Publication Date: 2012-03-14WISDOM PHARM CO LTD
3 Cites 1 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Publication Date
2012-03-14
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention relates to a novel synthesizing process for a linagliptin key intermediate, i.e., (R)-3-benzene dicarboximide piperidine tartrate. The novel synthesizing process comprises the following steps of: condensing (R)-3-amino piperidine hydrochloride with phthalic anhydride under the action of alkali to prepare (R)-3-benzene dicarboximide piperidine at a high yield; and conveniently and easily salifying the (R)-3-benzene dicarboximide piperidine and D-(-)-tartaric acid to obtain the (R)-3-benzene dicarboximide piperidine tartrate. The process has the advantages of low prices of raw materials used in each step, simple operation in each step, low equipment requirement, high security, easiness for post-treatment and purification operation, and suitability for industrial mass production.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention relates to a new process for synthesizing the key intermediate (R)-3-phthalimide piperidine tartrate of linagliptin. Background technique

[0002] Linagliptin is a new drug for treating diabetes developed by the international pharmaceutical giant Boehringer Ingelheim, and it is currently in the approval stage. In vitro studies have found that linagliptin is much more selective for the enzyme dipeptidyl peptidase (DPP) IV than for other DPPs; while in mice and rats, it has been observed that this product has a strong and long-lasting effect on DPP1V Inhibitory effect, and stronger than other DPPIV inhibitors. Clinical research results show that Linagliptin can increase the concentration of glucagon-like peptide (GLP-1), reduce the blood sugar concentration of patients with type II diabetes and significantly reduce the level of glycosylated hemoglobin (Hb1Ac) in patients with diabetes.

[0003] At present, Boehringer Ingelheim has carried...

Examples

Embodiment 1

[0018] Example 1 preparation( R )-3-phthalimide piperidine

[0019]

[0020] 500ml four-neck bottle, add compound 4 (40g), toluene (400mL), phthalic acid (34.2g) and triethylamine (47.8g), the system was refluxed to separate water for 48 hours, and the system was evaporated to dryness under reduced pressure. The residue was added with water (200mL) and ethyl acetate (300mL), then triethylamine (50g) was added, and the temperature of the system was raised to 30-40 o C. Stir until completely dissolved, let stand to separate the phases, extract the aqueous phase with ethyl acetate (80mL), and combine the organic phases. The organic phase was washed with saturated brine (2×100mL), dried, and the solvent was removed under reduced pressure to obtain ( R )-3-phthalimide piperidine crude product 63.7g. The product can be recrystallized from ethyl acetate to obtain 50 g of the product.

[0021]

Embodiment 2

[0022] Example 2 preparation( R )-3-phthalimide piperidine

[0023] 500ml four-neck bottle, add compound 4 (36g), benzene (300mL), phthalic acid (31.0g) and diisopropylethylamine (50g). After the system was refluxed to separate water for 36 hours, the system was evaporated to dryness under reduced pressure. The residue was added with water (180mL) and ethyl acetate (300mL), then diisopropylethylamine (50g) was added, and the temperature of the system was raised to 30-40 o C. Stir until completely dissolved, let stand to separate the phases, extract the aqueous phase with ethyl acetate (70mL), and combine the organic phases. The organic phase was washed with saturated brine (2×80mL), dried, and the solvent was removed under reduced pressure to obtain ( R )-3-phthalimide piperidine crude product 55.0g. The product can be recrystallized from ethyl acetate to obtain 42g of product.

[0024]

Embodiment 3

[0025] Example 3 preparation( R )-3-phthalimide piperidine-D-(-)-tartrate

[0026]

[0027] 250mL four-neck bottle, add ( R )-3-phthalimidepiperidine (25.2g) and EtOH (150mL), the system was heated to reflux, and the solid dissolved. The temperature of the system was slightly lowered, D-(-)-tartaric acid (13.05 g) was added, and the temperature was raised to reflux for 3 hours until a large amount of white solids were precipitated. The system cools down naturally to 0 o C, Buchner funnel suction filtration, the solid was washed with a small amount of ethanol, and the resulting solid was transferred to an oven for 45 o C was dried to obtain the product (36.7g). The product can be recrystallized in mixed solvents such as acetone / water and ethanol / water. Product purity: ≥99%.

[0028] 1 H NMR (300 MHz): δ 7.73-7.60 (m, 4H), 4.38 (m, 3H), 3.59 (t, J = 12.0 Hz, 1H), 3.39 (t, J = 12.0 Hz, 2H), 3.02-2.93 (t, J = 12.3 Hz, 1H), 2.29-2.16 (m, 1H), 2.02-1.67 (m, 3H).

...